

Systemic Therapy Update



BC Cancer Agency

CARE + RESEARCH

An agency of the Provincial Health Services Authority

May 2010
Volume 13, Number 5

For health professionals who care for cancer patients
Available online at www.bccancer.bc.ca/HPI/ChemotherapyProtocols/stupdate

INSIDE THIS ISSUE

- [Editor's Choice](#): 2010 /2011 New Drug Programs – Preliminary Information
- [Benefit Drug List](#): Capecitabine, Trastuzumab
- [Cancer Drug Manual](#) – **New**: Bendamustine
Revised: Aldesleukin, Temozolomide, Tamoxifen
Chemotherapy Stability Chart: Aldesleukin, Azacitidine, Temozolomide
- [Cancer Management Guidelines](#) – KRAS Test Requisition Form Updated
- [List of New and Revised Protocols, Pre-Printed Orders and Patient Handouts](#): **New**: LUSCPERT, LUAVPC, UMYBORPRE **Revised**: BRAVCAP, UGIAVCETIR, GIAVFL, UGIAVPANI, GIENDO2, UGIFOLFOX, GIFUIP, GOENDCAT, GOOVCATM, GOOVCATR, GOOVCATX, GOTDLR, GUBEP, GUEP, GUYEIP, GUVIP2, UGUTIP, ULKCMLN, LUAJNP, LYPALL, ULYRMTN, UMYBORTEZ, UMYLENDEX, UMYMPBOR, UMYTHALID, SMAJIFN
- [Website Resources and Contact Information](#)

EDITOR'S CHOICE:

2010 / 2011 NEW DRUG PROGRAMS – PRELIMINARY INFORMATION

The BC Cancer Agency Executive and the Systemic Therapy Program have made their preliminary decisions on the funding of the new programs requested for the fiscal year 2010/11, based on the reviews and recommendations by the agency's Priorities and Evaluation Committee (PEC). The following programs have been approved and funded for fiscal year 2010/11:

1. **Myeloma: Bortezomib** with **melphalan** and **prednisone** in new myeloma patients who are ineligible for allogeneic stem cell transplant (UMYMPBOR).

This program has been accessible through the BCCA Compassionate Access Program (CAP) since December 2009. It will continue to be funded for the rest of fiscal year 2010/11.

2. **Gastrointestinal: Trastuzumab** with **cisplatin** and **fluorouracil** or **capecitabine** as palliative treatment of metastatic or inoperable, locally advanced gastric or gastroesophageal junction adenocarcinoma (UGIGAVCCT, UGIGAVCFT, GIGAVTR).

This program has been accessible through CAP since February 2010. It will continue to be funded for the rest of fiscal year 2010/11.

At this time, the BC Cancer Agency has not received the final confirmation of the 2010/11 new oncology drug budget. Therefore, we are not able to advise on the timing and scope of implementation for the following programs:

1. **Genitourinary: Everolimus** in recurrent metastatic renal cell carcinoma failing tyrosine kinase inhibitors.

This drug is currently available through a pharmaceutical industry compassionate access program (AfiniTRAC® Reimbursement Support Program)

2. **Leukemia: Azacitidine** for advanced myelodysplastic syndrome.

This drug is currently available through a pharmaceutical industry compassionate access program (Vidaza® Access Program). Note that although this program has been extended indefinitely in BC, patients registered after 1 April 2010 may not be eligible for ongoing support when the program closes.

3. **Lung: Maintenance Pemetrexed** after first-line chemotherapy for Stage 3b and 4 non-small cell lung cancer

The following programs have not been approved for funding:

1. **Breast: Bevacizumab** in first-line treatment of metastatic breast cancer.
2. **Gynecological: Liposomal doxorubicin and carboplatin** in first recurrence of ovarian, primary peritoneal or fallopian adenocarcinoma.
3. **Lung: Gefitinib** for first-line metastatic non-small cell cancer with EGFR mutations.
4. **Myeloma: Bortezomib with melphalan and prednisone** in patients with myeloma who are eligible for allogeneic stem cell transplant.

CANCER DRUG MANUAL

Aldesleukin Monograph has been completely updated, with more details in:

- contraindications in significant cardiac, pulmonary, renal, hepatic or neurological impairment
- administration to take place only in hospitals with intensive care facilities
- severe toxicities associated with capillary leak syndrome
- neurologic changes, including changes in mental status, speech difficulties, ataxia, coma, etc., in patients without evidence of brain metastases

Bendamustine Interim Monograph has been developed. Bendamustine is a new alkylating agent related to mechlorethamine. It can only be accessed via Health Canada's Special Access Programme and requires approval by the BCCA Compassionate Access Program. Unlike mechlorethamine, it does not appear to cause phlebitis or sclerosis at intact injection sites. Bendamustine has been used in the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

Temozolomide Monograph and Handout have been updated:

- information on the injectable formulation added
- oral dosing information clarified to be consistent with BCCA protocols
- caution on birth control requirement clarified

Tamoxifen Monograph has been revised to include updated information regarding a rifampin-tamoxifen drug interaction. With the advent knowledge of endoxifen, an active metabolite of tamoxifen, the concurrent administration of rifampin and tamoxifen is no longer viewed as detrimental to efficacy because endoxifen level is not likely to be reduced.

Chemotherapy Preparation and Stability Chart has been revised:

- Aldesleukin information updated
- Azacitidine information added
- Temozolomide information added

BENEFIT DRUG LIST

The following treatment program has been added on the benefit drug list effective 1 May 2010:

- **Capecitabine** (case-by-case review) and **Trastuzumab** (case-by-case) in combination with cisplatin as palliative treatment of metastatic or inoperable, locally advanced gastric or gastroesophageal junction adenocarcinoma (UGIGAVCCT)
- Fluorouracil and **Trastuzumab** (case-by-case) in combination with cisplatin as palliative treatment of metastatic or inoperable, locally advanced gastric or gastroesophageal junction adenocarcinoma (UGIGAVCFT)

CANCER MANAGEMENT GUIDELINES

The **KRAS Testing Requisition Form** has been updated with:

- clarification to highlight the need to fax both the requisition to
 - the BC Cancer Agency **and**
 - the originating hospital of the representative tumour block
- reminder to use the online version of the form which remains the most current (www.bccancer.bc.ca/HPI/CancerManagementGuidelines/PathologyRequestForms)

LIST OF NEW AND REVISED PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

BC Cancer Agency Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below. Protocol codes for treatments requiring “Compassionate Access Program” (previously Undesignated Indications Request) approval are prefixed with the letter **U**.

NEW PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Protocol Title
LUSCPERT	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Therapy Of Limited Stage Small Cell Lung Cancer Using Cisplatin (Or Carboplatin) And Etoposide With Radiation
LUAVPC	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	First-Line Treatment Of Advanced Non-Small Cell Lung Cancer (NSCLC) With Carboplatin And Paclitaxel
UMYBORPRE	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Treatment of Multiple Myeloma Using Bortezomib with Dexamethasone as Induction Pre-Stem Cell Transplant

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
BRAVCAP	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility clarified</i>	Therapy for Metastatic Breast Cancer Using Capecitabine
UGIAVCETIR	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Exclusions clarified in protocol, option of magnesium sulphate added to PPPO</i>	Third Line Treatment of Metastatic Colorectal Cancer Using Cetuximab in Combination with Irinotecan

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
GIAVFL	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Tests clarified</i>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using 5-Fluorouracil Injection and Infusion and Folinic Acid (Leucovorin) Infusion
UGIAVPANI	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Safety information for infusion-related reactions clarified</i>	Palliative Third Line Treatment of Metastatic Colorectal Cancer Using Panitumumab
GIENDO2	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility clarified</i>	Palliative Therapy for Pancreatic Endocrine Tumours using Streptozocin and Doxorubicin
UGIFOLFOX	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility revised to include use after resection of solitary liver or lung metastases</i>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin, 5-Fluorouracil and Folinic Acid (Leucovorin)
GIFUIP	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Maximum dose of mitomycin added</i>	Chemotherapy of Pseudomyxoma Peritonei using intraperitoneal Mitomycin and Fluorouracil
GOENDCAT	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Clarifications in Tests</i>	Treatment of Primary Advanced or Recurrent Endometrial Cancer using Carboplatin and Docetaxel
GOOVCATM	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Clarifications in Tests</i>	Primary Treatment of No Visible Residual (Moderate-High Risk) Invasive Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer Using Carboplatin and Paclitaxel
GOOVCATR	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Clarifications in Tests</i>	Second Line Treatment of Invasive Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer Relapsing after Primary Treatment Using Paclitaxel and Carboplatin
GOOVCATX	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Clarifications in Tests</i>	Primary Treatment of Visible Residual (Extreme Risk) Invasive Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer Using Carboplatin and Paclitaxel
GOTDLR	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Methotrexate infusion rate clarified</i>	Therapy for Low Risk Gestational Trophoblastic Cancer Using Dactinomycin and Methotrexate
GUBEP	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Random glucose added to the Tests section</i>	Curative Therapy for Germ Cell Cancer Using Bleomycin, Etoposide and Cisplatin
GUEP	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Random glucose added to the Tests section</i>	Therapy for Nonseminoma Germ Cell Cancer Using Etoposide-Cisplatin
GUVEIP	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Clarifications in Test, Premedications and Treatment sections</i>	Consolidation/Salvage Treatment for Germ Cell Cancer Using Vinblastine, Cisplatin, Ifosfamide and Mesna
GUVIP2	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Random glucose added</i>	Nonseminoma Consolidation/Salvage Protocol using Etoposide, Cisplatin, Ifosfamide, MESNA
UGUTIP	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Random glucose added</i>	Therapy for Relapsed Testicular Germ Cell Cancer Using paclitaxel, Ifosfamide and Cisplatin (TIP)

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
ULKCMLN	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility revised</i>	Treatment of Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia using Nilotinib
LUAJNP	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Dose modification clarified</i>	Adjuvant Cisplatin And Vinorelbine Following Resection Of Non-Small Cell Lung Cancer
LYPALL	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility clarified</i>	Lymphoma Palliative Chemotherapy
ULYRMTN	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility clarified</i>	Maintenance Rituximab for Indolent Lymphoma
UMYBORTEZ	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Typo corrected in dosing for hepatic impairment</i>	Treatment of Multiple Myeloma using Bortezomib with Dexamethasone
UMYLENDEX	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Dosing modification for renal dysfunction clarified</i>	Therapy of Multiple Myeloma Using Lenalidomide with Dexamethasone
UMYMPBOR	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Typo corrected in dosing for hepatic impairment</i>	Treatment of Multiple Myeloma using Melphalan, Prednisone and Weekly Bortezomib
UMYTHALID	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility and Steroid Treatment sections clarified, caution on thromboembolic events added</i>	Therapy of Multiple Myeloma Using Thalidomide
SMAJIFN	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Time to proceed with treatment clarified</i>	Adjuvant Therapy of High Risk Malignant Melanoma with High Dose Interferon (HDIFN) alfa-2b.

WEBSITE RESOURCES AND CONTACT INFORMATION

WEBSITE RESOURCES	www.bccancer.bc.ca
REIMBURSEMENT AND FORMS: BENEFIT DRUG LIST, CLASS II, BC CANCER AGENCY COMPASSIONATE ACCESS PROGRAM	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Forms
CANCER DRUG MANUAL	www.bccancer.bc.ca/cdm
CANCER MANAGEMENT GUIDELINES	www.bccancer.bc.ca/CaMgmtGuidelines
CANCER CHEMOTHERAPY PROTOCOLS, PRE-PRINTED ORDERS, PROTOCOL PATIENT HANDOUTS	www.bccancer.bc.ca/ChemoProtocols
SYSTEMIC THERAPY PROGRAM POLICIES	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Policies
SYSTEMIC THERAPY UPDATE	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/stupdate

CONTACT INFORMATION	www.bccancer.bc.ca	
BC CANCER AGENCY	(604) 877-6000	Toll-Free 1-(800) 663-3333
PROVINCIAL SYSTEMIC THERAPY PROGRAM	Ext 2247	mlin@bccancer.bc.ca
COMMUNITIES ONCOLOGY NETWORK BUSINESS AFFAIRS.....	Ext 2744	david.leung@bccancer.bc.ca
UPDATE EDITOR	Ext 2288	mdelemos@bccancer.bc.ca
COMMUNITIES ONCOLOGY NETWORK PHARMACY EDUCATORS...	www.bccancer.bc.ca/RS/CommunitiesOncologyNetwork/Educators/Pharmacists/cap_bcca@bccancer.bc.ca
COMPASSIONATE ACCESS PROGRAM OFFICE	Ext 6277	cap_bcca@bccancer.bc.ca
DRUG INFORMATION	Fax (604) 708-2026	
EDUCATION RESOURCE NURSE	Ext 6275	druginfo@bccancer.bc.ca
NURSING PROFESSIONAL PRACTICE	Ext 2638	nursinged@bccancer.bc.ca
LIBRARY/CANCER INFORMATION.....	Ext 2623	ilundie@bccancer.bc.ca
OSCAR HELP DESK	1-(888)-675-8001.....	requests@bccancer.bc.ca
PHARMACY CHEMOTHERAPY CERTIFICATION	Ext 8003	
PHARMACY PROFESSIONAL PRACTICE	1-(888)-355-0355.....	oscar@bccancer.bc.ca
	Fax (604) 708-2051	
	(250) 712-3900	rxchemocert@bccancer.bc.ca
	Ext 686741	
	(250) 519.5574	jkippen@bccancer.bc.ca
ABBOTSFORD CENTRE (AC)	(604) 851-4710	Toll-free: 1-(877) 547-3777
CENTRE FOR THE SOUTHERN INTERIOR (CCSI)	(250) 712-3900	Toll-Free 1-(888) 563-7773
FRASER VALLEY CENTRE (FVCC)	(604) 930-2098	Toll-Free 1-(800) 523-2885
VANCOUVER CENTRE (VCC).....	(604) 877-6000	Toll-Free 1-(800) 663-3333
VANCOUVER ISLAND CENTRE (VICC)	(250) 519-5500	Toll-Free 1-(800) 670-3322

Editorial Review Board

Mário de Lemos, PharmD, MSc (Oncol) (Editor)
 Johanna Den Duyf, MA
 Poonam Kothare (Editorial clerk)
 Judy Oliver, BScN, MEd

Beth Morrison, MLS
 Jaya Venkatesh, MHA, CMA
 Susan Walisser, BSc (Pharm)